Risk Factors That Increase the Chance of Developing Primary Graft Dysfunction After Lung Transplantation
Launched by UNIVERSITY OF PENNSYLVANIA · Oct 31, 2007
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a serious lung problem called primary graft dysfunction (PGD), which can happen shortly after someone receives a lung transplant. Researchers want to understand if certain chemicals found in the blood can indicate a higher risk of developing PGD after surgery. By analyzing blood samples, the goal is to identify risk factors that could help doctors better manage care for patients undergoing lung transplants.
The trial is currently looking for participants who are planning to have a lung transplant or a combined heart and lung transplant. If someone is eligible, they will be asked to provide blood samples before and after their surgery. This study is open to all adults aged 18 years and older, but it does not include those receiving other types of combined organ transplants. Taking part in this trial could contribute to important findings that may improve outcomes for future lung transplant patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Undergoing lung or combined heart and lung transplantation
- Exclusion Criteria:
- • Undergoing combined organ transplantation other than heart and lung transplantation
About University Of Pennsylvania
The University of Pennsylvania, a prestigious Ivy League institution located in Philadelphia, is renowned for its commitment to advancing medical research and improving healthcare outcomes. As a clinical trial sponsor, the university leverages its extensive resources, interdisciplinary expertise, and cutting-edge facilities to conduct innovative studies across various therapeutic areas. With a focus on translating scientific discoveries into clinical applications, the University of Pennsylvania fosters collaborations among leading researchers, clinicians, and industry partners, ensuring rigorous trial design and adherence to ethical standards. Through its dedication to excellence in research and education, the university plays a pivotal role in shaping the future of medicine.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Philadelphia, Pennsylvania, United States
Patients applied
Trial Officials
Jason D. Christie, MD
Principal Investigator
University of Pennsylvania
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials